

PATENT COOPERATION TREATY



PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT
(PCT Article 36 and Rule 70)

REC'D 20 JAN 2005

PCT

23 MAR 2005

Applicant's or agent's file reference Case21414		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/PEA/416)	
International application No. PCT/EP 03/10294	International filing date (day/month/year) 16.09.2003	Priority date (day/month/year) 27.09.2002	
International Patent Classification (IPC) or both national classification and IPC C12P23/00			
Applicant DSM IP ASSETS B.V. et al.			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 6 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 2 sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the opinion</p> <p>II <input type="checkbox"/> Priority</p> <p>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p>IV <input type="checkbox"/> Lack of unity of invention</p> <p>V <input checked="" type="checkbox"/> Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI <input type="checkbox"/> Certain documents cited</p> <p>VII <input type="checkbox"/> Certain defects in the international application</p> <p>VIII <input type="checkbox"/> Certain observations on the international application</p>			
Date of submission of the demand 09.03.2004		Date of completion of this report 21.01.2005	
Name and mailing address of the International preliminary examining authority:  European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016		Authorized Officer Schneider, P Telephone No. +31 70 340-4523 	

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. **PCT/EP 03/10294**

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, Pages

1-9 as originally filed

Claims, Numbers

1-7 received on 05.10.2004 with letter of 05.10.2004.

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
 - ☐ the language of publication of the international application (under Rule 48.3(b)).
 - ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).
3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:
- ☐ contained in the international application in written form.
 - ☐ filed together with the international application in computer readable form.
 - ☒ furnished subsequently to this Authority in written form.
 - ☒ furnished subsequently to this Authority in computer readable form.
 - ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
 - ☒ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.
4. The amendments have resulted in the cancellation of:
- ☐ the description, pages:
 - ☐ the claims, Nos.:
 - ☐ the drawings, sheets:
5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. **PCT/EP 03/10294**

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;
citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes: Claims	1-7
	No: Claims	
Inventive step (IS)	Yes: Claims	
	No: Claims	1-7
Industrial applicability (IA)	Yes: Claims	1-7
	No: Claims	

2. Citations and explanations

see separate sheet

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

The following documents (D) are referred to in this communication; the numbering will be adhered to in the rest of the procedure:

- D1: US-B1-6 291 204 (PASAMONTES LUIS ET AL) 18 September 2001 (2001-09-18)
- D2: US-B1-6 365 386 (HOSHINO TATSUO ET AL) 2 April 2002 (2002-04-02)
- D3: EP-A-1 111 067 (HOFFMANN LA ROCHE) 27 June 2001 (2001-06-27)
- D4: MISAWA NORIHIKO ET AL.; BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 209, no. 3, 1995, pages 867-876

1 Amendments (Art. 28 PCT)

A new set of claims has been filed with a letter dated 05.10.2004, received 05.10.2004. The subject matter of new claim 6 relates to a process carried out at a pH in the range of 3 to 7. This specific pH range is not disclosed in the application as filed and therefore constitutes unallowable subject matter under Art. 28(2) PCT.

2 Novelty (Art. 33(2) PCT)

No prior art document can be seen that discloses a β -carotene accumulating microorganism of the genus *Xanthophyllomyces* (Phaffia) that additionally expresses a β -carotene ketolase gene from *Agrobacterium*, *Alcaligenes*, *Paracoccus* or *Haematococcus*. The subject matter of claims 1 to 7 is therefore new under Art. 33(2) PCT.

3 Inventive Step (Art. 33(3) PCT EPC)

3.1 D2 is the closest prior art and discloses the carotenogenic yeast strain *P. rhodozyma* ATCC96815 (e.g. col. 8, 3rd par.) which is blocked for the production astaxanthin and which

accumulates e.g. echinenone and canthaxanthin (col. 4 2nd par.) and which was stated to be used by the present application (see page 8, example 2). D2 also discloses the asthaxanthin biosynthetic pathway with all intermediates (i.a. echinenone and canthaxanthin produced by crtW, FIG.1)

From D2 the present application differs in that a β -carotene ketolase gene (crtW) from *Agrobacterium*, *Alcaligenes*, *Paracoccus* or *Haematococcus* is expressed in said yeast strain.

The technical effect that is associated with said difference in the enhanced production echinenone and canthaxanthin. The simplification of their purification is already inherently comprised by D2 due to the absence of astaxanthin.

The problem to be solved is therefore the provision of an enhanced production process for echinenone and canthaxanthin.

3.2 Document D1 relates to the improved fermentative production of carotenoids, i.a. echinenone and canthaxanthin (col. 1, 2nd and 4th par.), therefore the skilled person trying to solve the technical problem posed would clearly combine D1 and D2.

D1 discloses the β -carotene ketolase genes crtW from *Agrobacterium*, *Alcaligenes PC-1* and *Haematococcus* to be expressed in *E.coli* for the production of canthaxanthin via echinenone (col.1). It also mentions the carotenogenic fungus *Phaffia* (written as "Pfaffia" which is an obvious error).

By combining D1 and D2 the skilled person would clearly introduce the crtW genes from D1 (or from any other microorganism) into the *Phaffia* strain from D2 and would arrive at the subject matter of the present application with a reasonable expectation of success without exercising inventive skills. As a consequence, the subject matter of claims 1 to 7 is not inventive under Art. 33(3) PCT.

4 Apart from the above-mentioned the present claims fulfill the requirement of industrial applicability (Art. 33(4) PCT).

5 Clarity (Art. 6 PCT)

The term "substantially homologous" used in claim 5 is vague and unclear and leaves the reader in doubt as to the meaning of the technical features to which it refers, thereby rendering the definition of the subject matter of said claim unclear (Art. 6 PCT).

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP 03/10294

PCT/EP03/10294
DSM IP ASSETS B.V.

Claims:

1. A process for producing canthaxanthin and echinenone which comprises cultivating a recombinant microorganism which is expressing a β -carotene ketolase gene and belonging to the genus *Xanthophyllomyces* (*Phaffia*) and which accumulates β -carotene in an aqueous nutrient medium under aerobic conditions, and isolating the resulted carotenoids from the cells of said recombinant microorganism or from the cultured broth, wherein the β -carotene ketolase gene is originated from a microorganism which is selected from the group consisting of microorganisms of the genera *Agrobacterium*, *Alcaligenes*, *Paracoccus* and *Haematococcus* having the β -carotene ketolase gene.
2. The process according to claim 1, wherein the recombinant microorganism is derived from *Xanthophyllomyces dendrorhous* (*Phaffia rhodozyma*) ATCC96815, or a mutant thereof.
3. The process according to claim 1, wherein the β -carotene ketolase gene is originated from a microorganism which is selected from the group consisting of *Agrobacterium aurantiacum*, *Alcaligenes* PC-1, *Paracoccus marcusii* MH1, a gram-negative bacteria E-396 (FERM BP-4283), and *Haematococcus pluvialis*, having the β -carotene ketolase gene.
4. The process according to claim 1, wherein the β -carotene ketolase gene is originated from *Alcaligenes* PC-1 or the DNA sequence of the β -carotene ketolase gene is substantially homologous thereto.
5. The process according to claim 1, wherein the β -carotene ketolase gene is expressed in the recombinant microorganism using the control sequences.
6. The process according to claim 1, wherein the cultivation is carried out at a pH in the range of from 3 to 7 and at a temperature in the range of from 15 to 26°C for 24 to 500 hours.

7. The process according to claim 7, wherein the cultivation is carried out at a pH in the range of from 5 to 7 and at a temperature in the range of from 18 to 22°C for 48 to 350 hours.